data 2014

data 2014

data 2014

Product catalog summary
Overview: Kawasumi Laboratories, Inc. is a Tokyo-based company specializing in the manufacturing and sales of medical devices and pharmaceuticals. Established in 1957, the company is led by President and CEO Yukihiro Kawano and is listed on the TSE 2nd Section.
Financial Data: The document provides consolidated financial data from 2006 to 2014, including net sales, operating income, net income, total assets, and net assets. Key metrics such as ROA, ROE, equity turnover, equity ratio, current ratio, and fixed ratio are detailed, showing trends in sales, income, and asset management.
Business Segments: Kawasumi operates in two main segments: 'Blood Transfusion and Endovascular' and 'Hemodialysis and Plasmapheresis'. Products include blood bags, blood collection devices, catheters, stent grafts, dialyzers, and apheresis machines, supporting global medical treatments.
Product Offerings: Main products include blood bags, stent grafts, blood collection devices, potassium adsorption filters, dialyzers, blood tubing lines, and A.V. fistula needles, emphasizing safety and efficiency in medical procedures.
Cash Flow Analysis: Detailed cash flow statements highlight cash flows from operating, investing, and financing activities, showing net cash trends over the years.
Exchange Rates and Geographical Segments: The document includes average exchange rates for USD, EUR, and THB, and financial performance by geographical segments: Japan, the Americas, Europe, Asia, and Oceania.
Conclusion: Kawasumi Laboratories, Inc. has demonstrated consistent growth and expansion, focusing on medical devices for blood-related treatments and hemodialysis, with strategic investments and operational efficiency.
Company Overview: As of March 31, 2014, the company had a paid-in capital of ¥6,642 million. Subsidiaries include Kawasumi Laboratories (Thailand) Co., Ltd., Kawasumi Laboratories America, Inc., and others.
Share Information: As of March 31, 2014, 22,948,003 shares were issued and outstanding, with 2,858 shareholders. Shareholder distribution includes individuals (29.68%), other Japanese companies (30.10%), financial institutions (21.45%), foreign companies (17.68%), and others.
Major Shareholders: The top shareholders include Kuraray Co., Ltd., Asahi Kasei Medical Co., Ltd., and Terumo Corporation, with Kuraray Co., Ltd. holding the largest share at 9.89%.
See more

Catalog excerpts

data 2014-2

Kawasumi has two business segments; "Blood Transfusion and Endovascular" and "Hemodialysis and Plasmapheresis" Blood Transfusion and Endovascular Hemodialysis and Plasmapheresis <Blood Banking and Transfusion> Blood-related medical devices such as Blood Bags, Blood Collection Device, and Apheresis Kits are used for blood collection, production and preserve of blood products. Kawasumi provides these devices to support the demand of safe blood. <Endovascular Repair> Kawasumi develops minimally invasive and highly-functional products such as Catheters and Stent Graft which are used for Endovascular...

 Open the catalog to page 2
data 2014-3

Consolidated Financial Highlights mSS-mSWWa / Blood Transfusion and Endovascular I cEailt^USS Operating Income • Operating income ^H^y§£$ / Operating income to net sales tyy — *3F-Vyz/3.'yO— Free Cash Flow i flow = Cash flow from operating activities + Cash flow from investing activities Note: A triangle (shown as" .") denotes a negative number.

 Open the catalog to page 3
data 2014-4

Financial Data I §5S$illi? Equity Turnover I §2St^tfc^ Equity Ratio I JmUjtfc^ Current Ratio I HDAE!!:!^ Fixed Ratio ;±: ROA = SS« + e«S («*¥)*)) X100 gS«*B$i* = 5E±?B + Se«*«S*¥eB Sffl&tt* = SfflMtS + »@fll x 100 ROE = SlWtfflffi + g3«*(ISS*¥E)) x 100 gS«*hW = Mftg + SUS x 100 BStt* = BSHSx 100

 Open the catalog to page 4
data 2014-5

Financial Data Capital Expenditures (HSR/¥ Million) (HSR/¥ Million) 11 ^fc^TcUMSIS Net Assets per Share 11 ffimrcVmmmm Net income per Share 11 ^^TcUIS^^^F^) Annual Cash Dividends per Share Notes: ROA = Ordinary income / Total assets(yearly average) x 100 Equity turnover = Net sales / Equity capital(yearly averag ROE = Net income / Equity capital(yearly average) x 100 Equity ratio = Net assets / Total assets x 100 Current ratio = Current assets / Current liabilities x 100 Fixed ratio = Fixed assets / Equity capital x 100

 Open the catalog to page 5
data 2014-6

Consolidated Financial Statements I J^lnlJfEi^tP,Ri^ Consolidated Balance Sheets (SBP3 /¥ Million)

 Open the catalog to page 6
data 2014-7

Consolidated Financial Statements Consolidated Statements of Cash Fows ^^SBjIi-^'S+l'iyi^n.'^n- Cash flow from operating activities:

 Open the catalog to page 7
data 2014-8

Investor Information Company Data Company name Head office Paid-in capital Fiscal year-end Kawasumi Laboratories, Incorporated Shinagawa Intercity Tower B, 9th Floor 2-15-2, Konan, Minato-ku Yukihiro Kawano President and Chief Executive Officer Main businesses Manufacturing and sales of medical devices and pharmaceuticals ti^X- ^Tff^HJ-X^U^INC. Kawasumi Laboratories (Thailand) Co., Ltd. Kawasumi Laboratories America, Inc. Kawasumi Platech Incorporated ■ ^lCO^?5E(2014^3^31 BfflE) Share Information (As of March 31, 2014) Authorized number of shares 50,000,000 ** PifT>n$fclC©§§iS(g34*a£S£)) Total...

 Open the catalog to page 8

All Kawasumi catalogs and technical brochures

  1. 2011

    8  Pages

  2. 2012

    8  Pages

  3. data 2013

    8  Pages

  4. DATA BOOK

    8  Pages

*Prices are pre-tax. They exclude delivery charges and customs duties and do not include additional charges for installation or activation options. Prices are indicative only and may vary by country, with changes to the cost of raw materials and exchange rates.